Compare Danaher Corporation (DHR) vs Xylem, Inc. (XYL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Xylem, Inc. — how do they compare? Danaher Corporation trades at $219.8 (market cap $152.87B), while Xylem, Inc. trades at $103 (market cap $23.81B). The key difference: Danaher Corporation is far larger — about 6.4× Xylem, Inc.'s market cap, and Xylem, Inc. pays the higher dividend (1.69%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Xylem, Inc. for 50 Days on average.
| DHR | XYL | |
|---|---|---|
Market Cap | $152.87B | $23.81B |
Volume | 5,228,698 | 2,234,713 |
Sector | Health | Industrials |
52-Week High | $242.05 | $152.95 |
52-Week Low | $161.91 | $100.92 |
Typical Hold Time | 69 Days | 50 Days |
Enterprise Value | $175.08B | $25.59B |
Dividend Yield | 0.74% | 1.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $218.49, up 1.36% on the day, with a bullish technical signal and consistent earnings beats in recent quarters. The stock shows strong profitability with a 58.51% gross margin and 15.95% net income margin, though revenue growth has been modest. Analyst consensus is strongly bullish with a $230.31 price target, supported by institutional buying activity and a recent dividend announcement.
The outlook for DHR is positive, driven by earnings momentum and institutional confidence, but risks include elevated valuation multiples and competitive pressures in the healthcare sector. Investors should weigh the strong analyst support against potential margin compression and macroeconomic headwinds affecting capital spending.
XYL trades at $102.71, up 0.86% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $9.04B in 2025 with a net income margin of 10.59%, and has beaten EPS estimates in recent quarters. Recent developments include a $1.5B senior note offering to fund acquisitions of Cornell Pump and Roper Pump, and the appointment of a new CFO.
Outlook is supported by strong water-solutions demand and margin expansion, but risks include China weakness and higher debt. Analysts are mixed with a consensus price target of $149.13, implying significant upside from current levels, though near-term technical pressure may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Xylem, Inc.
Xylem is a global leader in water technology and offers a wide range of solutions, including the transport, treatment, testing, and efficient use of water for customers in the utility, industrial, commercial, and residential sectors. Xylem was spun off from ITT in 2011. Based in Rye Brook, New York, Xylem has a presence in over 150 countries and employs 16,200. The company generated $6.2 billion in revenue and $611 million in adjusted operating income in 2021.
Read more on XYL →
